The large-scale trial seeks to enroll 410,000 healthy Danish adults age 65 and older. The study will compare Moderna’s combination mRNA COVID-19 and flu shot with two separate shots: Moderna’s Spikevax COVID-19 vaccine and its high-dose flu vaccine. Scientists and physicians critical of mRNA vaccines warned the trial could expose a third of the Danish population to serious vaccine injuries.

  • Moderna’s DAN-COMBO trial will compare its mRNA-1083 COVID-flu combination vaccine with separate COVID-19 and high-dose flu shots in up to 410,000 Danish adults age 65 and older.
  • Scientists and physicians critical of mRNA vaccines are raising concerns about the trial’s design, including the lack of a placebo group and the fact that participants will know which vaccines they received.
  • Critics also question the use of Moderna’s high-dose flu vaccine as the comparator, arguing that its reported adverse-event profile could make the combination vaccine appear more favorable.
  • The article cites clinical-trial data and analyses from critics who say Moderna’s high-dose flue vaccine was associated with higher rates of serious adverse events and deaths than comparison flu vaccines, while Moderna’s vaccine nonetheless received FDA approval in 2026.
  • Critics also point to an earlier mRNA-1083 trial in which participants age 65 and older reportedly had 38% higher odds of a serious adverse event than those in the control group.
  • Critics cited additional concerns about lipid nanoparticles, potential DNA contamination and vaccine effectiveness, and called for greater scrutiny of the large new trial.

https://tdefender.substack.com/p/moderna-plan-test-mrna-covid-flu-vaccines-410000-elderly-catastrophe-making-critic-says?